Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Latest Update Results of Cmoep Regimen in Treatment-Naive Patients with Peripheral T-Cell Lymphoma

Jingwei Yu, Xiuhua Sun, Guangxun Gao, Li Yu, Jiesong Wang, Lihua Qiu, Zhengzi Qian, Wei Li, Huilai Zhang

Blood (2024) 144 (Supplement 1): 6403.

https://doi.org/10.1182/blood-2024-204337

Published: 2024

Journal Articles

Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)

Jie Jin, Liling Zhang, Liqun Zou, Zengjun Li, Huijing Wu, Keshu Zhou, Lihua Qiu, Liping Su, Kaiyang Ding, Hui Zhou, Li Yu, Fei Li, Qing Xiao, Wenyu Li, Lie Lin, Erhua Wang, Lijia Chen, Qingqing Cai

Blood (2024) 144 (Supplement 1): 6368.

https://doi.org/10.1182/blood-2024-211891

Published: 2024

Journal Articles

Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World, Multi-Center, Retrospective Cohort Study

Zhao Peiqi, Shu Zhao, Chen Huang, Jiesong Wang, Junqing Xu, Lanfang Li, Zhengzi Qian, Wei Li, Shiyong Zhou, Lihua Qiu, Xianming Liu, Ying Chen, Yanan Jiang, Yanbin Zheng, Daoguang Chen, Yuhuan Gao, Qingyuan Zhang, Huilai Zhang

Blood (2024) 144 (Supplement 1): 3730.

https://doi.org/10.1182/blood-2024-205438

Published: 2024

Journal Articles

Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2023) 142 (Supplement 1): 6145.

https://doi.org/10.1182/blood-2023-177820

Published: 2023

Journal Articles

A Prospective Multicenter Phase II Study of Orelabrutinib-Lenalidomide-Rituximab (OLR) in Patients with Untreated Mantle Cell Lymphoma (MCL) in China (POLARIS Study): Preliminary Analysis on Efficacy, Safety, Mutation Spectrum and Impact of Mutation Profiling on Treatment Responses

Huilai Zhang, Liping Su, Lihong Liu, Ou Bai, Zheng Song, Zhiqiang Zhao, Cuiying He, Qiang Guo, Xianhuo Wang, Wei Li, Lihua Qiu, Lanfang Li, Shiyong Zhou, Yue Fei, Xiaohui Wang, Bin Meng

Blood (2023) 142 (Supplement 1): 736.

https://doi.org/10.1182/blood-2023-178509

Published: 2023

Journal Articles

PI3Kδ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial

Blood (2023) 142 (Supplement 1): 1677.

https://doi.org/10.1182/blood-2023-178710

Published: 2023

Journal Articles

CD58 Genetic Alterations and Its Contribution to Upregulation of PD-L1 and IDO Via LYN/CD22/SHP1 Axis in DLBCL

Xiyue Xu, Qingpei Guan, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Yixin Yao, Xianhuo Wang, Huilai Zhang

Blood (2023) 142 (Supplement 1): 524.

https://doi.org/10.1182/blood-2023-188468

Published: 2023

Journal Articles

Azacitidine for Injection Combined with Chidamide in Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase I Study

Jingwei Yu, Yaxiao Lu, Yixin Yao, Xianming Liu, Lanfang Li, Zhengzi Qian, Lihua Qiu, Shiyong Zhou, Xianhuo Wang, Huilai Zhang

Blood (2023) 142 (Supplement 1): 3076.

https://doi.org/10.1182/blood-2023-188801

Published: 2023

Journal Articles

Phase 2 Study of Golidocitinib, a JAK1 Selective Inhibitor, As Maintenance Therapy in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy (JACKPOT26)

Jie Jin, Qingqing Cai, Liling Zhang, Liqun Zou, Zengjun Li, Huijing Wu, Keshu Zhou, Lihua Qiu, Liping Su, Kaiyang Ding, Hui Zhou, Li Yu, Fei Li, Qing Xiao, Wenyu Li, Lie Lin, Erhua Wang, Lijia Chen

Blood (2023) 142 (Supplement 1): 4430.

https://doi.org/10.1182/blood-2023-185543

Published: 2023

Journal Articles

Dose Adjustments of Linperlisib in Relapsed or Refractory Follicular Lymphoma: A Post-Hoc Analysis of a Pivotal Phase II Study

Blood (2023) 142 (Supplement 1): 6140.

https://doi.org/10.1182/blood-2023-180373

Published: 2023

Journal Articles

Combination of Baseline Total Metabolic Tumor Volume Measured on FDG-PET/CT, ECOG Performance Status and β2-Microglobulin Have a Robust Predictive Value in Patients with Primary Breast Lymphoma

Peiqi Zhao, Lei Zhu, Lanfang Li, Shiyong Zhou, Lihua Qiu, Kai Fu, Huilai Zhang

Blood (2022) 140 (Supplement 1): 3805–3806.

https://doi.org/10.1182/blood-2022-158674

Published: 2022

Journal Articles

Upconversion Optogenetic Engineered Bacteria System for Time-Resolved Imaging Diagnosis and Light-Controlled Lymphoma Therapy

Peiqi Zhao, Shiyong Zhou, Lihua Qiu, Lanfang Li, Zhengzi Qian, Kai Fu, Huilai Zhang

Blood (2022) 140 (Supplement 1): 6008–6009.

https://doi.org/10.1182/blood-2022-158434

Published: 2022

Journal Articles

Immune Checkpoints Involving the PD-1/PD-L1/L2 and CD73/A2aR Axes and the Immunosuppressive Microenvironment in DLBCL

Xianhuo Wang, Tingting Zhang, Hengqi Liu, Sicong Zhang, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Kai Fu, Huilai Zhang

Blood (2022) 140 (Supplement 1): 6458–6459.

https://doi.org/10.1182/blood-2022-165060

Published: 2022

Journal Articles

PIM1 Genetic Alterations Associated with Distinct Molecular Profiles, Phenotypes and Drug Responses in Diffuse Large B-Cell Lymphoma

Xianhuo Wang, Yaxiao Lu, Sicong Zhang, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Kai Fu, Huilai Zhang

Blood (2022) 140 (Supplement 1): 9264–9265.

https://doi.org/10.1182/blood-2022-164976

Published: 2022

Journal Articles

Comprehensive Analysis of TP53 and CD58 Mutations and Identification of Patients with Inferior Prognosis and Enhanced Immune Escape in Diffuse Large B Cell Lymphoma

Xianhuo Wang, Tingting Zhang, Yaxiao Lu, Yue Fei, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Kai Fu, Huilai Zhang

Blood (2022) 140 (Supplement 1): 9236–9237.

https://doi.org/10.1182/blood-2022-164603

Published: 2022

Journal Articles

Biological and Clinical Significance of PIM1 Genetic Alterations in Diffuse Large B-Cell Lymphoma

Xianhuo Wang, Yaxiao Lu, Yue Fei, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Kai Fu, Huilai Zhang

Blood (2021) 138 (Supplement 1): 3494.

https://doi.org/10.1182/blood-2021-150405

Published: 2021

Journal Articles

Plasma Soluble Programmed Death Ligand 1 Levels Predict Clinical Response in Peripheral T-Cell Lymphomas

Xianhuo Wang, Xuhan Zhang, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Bin Meng, Xiubao Ren, Kai Fu, MD PhD, Huilai Zhang

Blood (2019) 134 (Supplement_1): 5231.

https://doi.org/10.1182/blood-2019-124266

Published: 2019

Journal Articles

CD5 Expression Correlates with Inferior Survival and Enhances the Negative Effect of p53 Overexpression in Diffuse Large B Cell Lymphoma

Peiqi Zhao, Huilai Zhang, MD, Kai Fu, MD PhD, Xianhuo Wang, MD, Lanfang Li, Zhengzi Qian, Lihua Qiu, Shiyong Zhou

Blood (2019) 134 (Supplement_1): 4117.

https://doi.org/10.1182/blood-2019-127666

Published: 2019

Journal Articles

Evaluation of the Prognostic Significance and Effect of NT5E-Adenosine Axis, a Novel Immune Checkpoint, in Diffuse Large B-Cell Lymphoma

Xianhuo Wang, Tingting Zhang, Lanfang Li, Lihua Qiu, Zhengzi Qian, Shiyong Zhou, Bin Meng, Xiubao Ren, Huilai Zhang, Kai Fu, MD PhD

Blood (2019) 134 (Supplement_1): 2801.

https://doi.org/10.1182/blood-2019-124233

Published: 2019

NARROW

Latest Update Results of Cmoep Regimen in Treatment-Naive Patients with Peripheral T-Cell Lymphoma

Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)

Efficacy and Safety of Polatuzumab-Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone (Pola-R-CHP) for Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): A Real-World, Multi-Center, Retrospective Cohort Study

Subgroup Analysis from a Phase 2, Single-Arm Trial of the Oral PI3Kδ Inhibitor Linperlisib in Patients with Relapsed or Refractory Follicular Lymphoma

A Prospective Multicenter Phase II Study of Orelabrutinib-Lenalidomide-Rituximab (OLR) in Patients with Untreated Mantle Cell Lymphoma (MCL) in China (POLARIS Study): Preliminary Analysis on Efficacy, Safety, Mutation Spectrum and Impact of Mutation Profiling on Treatment Responses

PI3Kδ Inhibitor Linperlisib As a ≥ 3-Line Treatment for Relapsed or Refractory Follicular Lymphoma: A Subgroup Analysis of a Phase II, Single-Arm, Open-Label Trial

CD58 Genetic Alterations and Its Contribution to Upregulation of PD-L1 and IDO Via LYN/CD22/SHP1 Axis in DLBCL

Azacitidine for Injection Combined with Chidamide in Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase I Study

Phase 2 Study of Golidocitinib, a JAK1 Selective Inhibitor, As Maintenance Therapy in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy (JACKPOT26)

Dose Adjustments of Linperlisib in Relapsed or Refractory Follicular Lymphoma: A Post-Hoc Analysis of a Pivotal Phase II Study

Combination of Baseline Total Metabolic Tumor Volume Measured on FDG-PET/CT, ECOG Performance Status and β2-Microglobulin Have a Robust Predictive Value in Patients with Primary Breast Lymphoma

Upconversion Optogenetic Engineered Bacteria System for Time-Resolved Imaging Diagnosis and Light-Controlled Lymphoma Therapy

Immune Checkpoints Involving the PD-1/PD-L1/L2 and CD73/A2aR Axes and the Immunosuppressive Microenvironment in DLBCL

PIM1 Genetic Alterations Associated with Distinct Molecular Profiles, Phenotypes and Drug Responses in Diffuse Large B-Cell Lymphoma

Comprehensive Analysis of TP53 and CD58 Mutations and Identification of Patients with Inferior Prognosis and Enhanced Immune Escape in Diffuse Large B Cell Lymphoma

Biological and Clinical Significance of PIM1 Genetic Alterations in Diffuse Large B-Cell Lymphoma

Plasma Soluble Programmed Death Ligand 1 Levels Predict Clinical Response in Peripheral T-Cell Lymphomas

CD5 Expression Correlates with Inferior Survival and Enhances the Negative Effect of p53 Overexpression in Diffuse Large B Cell Lymphoma

Evaluation of the Prognostic Significance and Effect of NT5E-Adenosine Axis, a Novel Immune Checkpoint, in Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only